A 12-Week Treatment, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Indacaterol (150 and 300 microg o.d.) in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A 12-Week Treatment, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Indacaterol (150 and 300 microg o.d.) in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 28 Nov 2011 Results published in Respirology.
    • 18 May 2011 Results presented at the 107th International Conference of the American Thoracic Society.
    • 23 Jun 2010 New source identified and integrated (Clinical Trials Registry - India).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top